The new General Director short-term goals include driving the company's growth and supporting innovation in products based on Artificial Intelligence, the value of data and blockchain.
Pedro Arellano has more than 20 years of professional experience in management positions, among them he has been Deputy to the General Management and responsible for Corporate Development at the Port of Barcelona.
As part of its growth strategy, Enzyme continues to invest in and attract talent; to this end, the company plans to reinforce its team of more than 100 professionals with the incorporation of 20 additional highly specialized profiles.
Enzyme celebrated its tenth anniversary in 2021 by announcing plans for international expansion, exceeding its turnover targets and estimating 18% of growth by 2022. In addition, this past year it launched Komombo, its first Artificial Intelligence product for the healthcare sector developed with Hospital Clínic of Barcelona.
Barcelona, January 10th, 2022.- Enzyme Advising Group, a company specialized in accelerating the growth of companies through technology, has appointed Pedro Arellano as General Director. With this appointment, Arellano assumes the responsibility of managing Enzyme's operations, to strengthen growth and relationships with customers and partners, implementing Enzyme's strategic lines. Álvaro Ortín, current CEO, will lead the company's global strategy and direct the international expansion of the company.
"I take on this professional challenge with the desire to contribute my experiences to Enzyme and support the professional development of the team," says Arellano, who has also expressed his determination to "drive the growth of the company, both in our strategic business lines and innovating in products based on Artificial Intelligence, the value of data and blockchain."
For his part, Álvaro Ortín affirms that "incorporating a profile like Pedro's to our management team is key in this stage of growth and international expansion of the company. His strategic, innovative and entrepreneurial vision, in addition to his ability to work with heterogeneous teams, will provide us with that differential point that will allow us to address the following stages of Enzyme."
A valuable professional career
Pedro Arellano has a solid and diversified professional background, with more than 20 years of experience in sectors such as logistics, education, health, technology, industry and consumer goods, which brings across-cutting and valuable perspective to Enzyme. In his last stages he has been CEO of TalentClue, as well as Assistant to General Management and responsible for Corporate Development of the Port of Barcelona, being also linked to the development of several startups. He is an expert in corporate change processes and strategic implementation, public-private partnerships and family businesses.
Arellano holds a PDG from IESE, an MBA from ESADE, a degree in Labor Sciences and a diploma in Family Business Consulting from the Family Firm Institute.
Enzyme, 10 years as a technology partner of the best companies
In 2021, Enzyme Advising Group celebrated its tenth anniversary by announcing that it met and exceeded its turnover targets and that its forecast for this 2022 is to grow by more than 18%.
It also revealed the launch of an ambitious international growth strategy and the intention to expand its current team of more than 100 professionals with another 20 highly specialized profiles to respond to the services required by its clients and help develop "platform as a service" products, such as Komombo, the first Artificial Intelligence product for the healthcare sector developed with the Hospital Clínic de Barcelona.
In its decade of business life, the company has established itself as a leader in Spain in providing Artificial Intelligence technology solutions to its more than 130 clients from different sectors both nationally and internationally.
Press Summary
